because there was no money, or because an agreement was made with an unreliable partner (the Chinese at the end of February), because there were no lenders / big Pharma willing to invest in us, because Moscato did not involve the old shareholders with a capital increase , because Barda & company did not pay a cent, because Ngio was not listed within the promised time frame (due to delays not only attributable to Gnbt), because Excellagen did not generate income as hoped, etc.